** U.S.-listed shares of Switzerland-based drug developer Oculis Holding CR5.F, OCS.O rise 6.8% to $18.75 premarket

** Co says its drug, OCS-05, met the main goal of safety in a mid-stage trial testing it in patients with acute optic neuritis, an inflammatory condition that causes sudden vision loss

** Says the drug also improved patients' visual function during the trial

** Up to last close, stock up 66.3% in the last 12 months

(Reporting by Christy Santhosh)

((Christy.Santhosh@thomsonreuters.com))